Table 1. Baseline characteristics of patients with POAF from the included studies.
| Study | Sample size
(n) |
Age
(mean ± SD) |
Male
n (%) |
Hypertension
n (%) |
Diabetes
n (%) |
Hyperlipidemia
n (%) |
Renal
failure n(%) |
CHF
n (%) |
COPD
n (%) |
Current
Smoker n (%) |
Follow up
duration (yrs) |
| CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; POAF: postoperative atrial fibrillation. | |||||||||||
| Almassi 2012[8] | 551 | 65.3 ± 8.5 | 551
(100%) |
494
(90%) |
254
(46%) |
− (−) | − (−) | − (−) | 130
(24%) |
154
(28%) |
1 |
| Almassi 2014[9] | 549 | 65.8 ± 8.5 | 549
(100%) |
492
(89.6%) |
216
(39.3%) |
− (−) | − (−) | − (−) | 130
(23.7%) |
153
(27.9%) |
1 |
| Batra 2019[10] | 2290 | 70 ± 5 | 1884
(82.3%) |
1697
(74.1%) |
675
(29.5%) |
− (−) | 56
(2.4%) |
406
(17.7%) |
138
(6%) |
− (−) | 2.2 |
| Bramer 2010[11] | 1122 | 68.5 ± 8.1 | 884
(78.8%) |
578
(54.5%) |
232
(20.7%) |
− (−) | − (−) | − (−) | 130
(11.6%) |
− (−) | 2.5 |
| de Oliveira 2007[12] | 397 | 67.6 ± 8.7 | 297
(75%) |
301
(75.8%) |
119
(29.9%) |
194
(48.8%) |
− (−) | 68
(17.1%) |
− (−) | 145
(36.5%) |
Unspecified |
| Fensgrud 2017[13] | 165 | 69.2 ± 7.6 | 134
(81%) |
59
(36%) |
28
(17%) |
− (−) | − (−) | − (−) | − (−) | 94
(57%) |
15 |
| Kalavrouziotis 2007[15] | 2047 | < 60 16.2%
60−69 31.9% 70−79 40.6% > 80 11.4% |
1537
(75.1%) |
1310
(64%) |
692
(33.8%) |
− (−) | 151
(7.4%) |
348
(17%) |
342
(16.7%) |
− (−) | Unspecified |
| Konstantino 2016[2] | 37 | 76 ± 7 | 25
(68%) |
31
(84%) |
13
(35%) |
37
(100%) |
− (−) | − (−) | 6
(16%) |
8
(22%) |
8.5 |
| Mankad 2019[16] | 400 | 68.9 | 200
(100%) |
171
(85.5%) |
83
(41.5%) |
− (−) | − (−) | 113
(56.5%) |
− (−) | − (−) | 5 |
| Mariscalco 2009[17] | 2535 | 69.3 ± 7.9 | 1778
(70.1%) |
1554
(61.3%) |
487
(19.2%) |
− (−) | − (−) | − (−) | − (−) | − (−) | 7.9 |
| Saxena 2012[14] | 5547 | 69.04 ± 9.03 | − (−) | 4425
(79.8%) |
1786
(32.2%) |
4500
(81.1%) |
200
(3.6%) |
967
(17.4%) |
773
(13.9%) |
− (−) | 3.66 |